Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 30,427 articles published since 2009
|||| 45 

These are the 30427 published articles about Pancreatic Neoplasms that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
276 Editorial When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward. 2015

Lyman, Gary H / Kuderer, Nicole M. ·Fred Hutchinson Cancer Research Center, University of Washington; and Seattle Cancer Care Alliance, Seattle, WA glyman@fredhutch.org. · University of Washington; and Seattle Cancer Care Alliance, Seattle, WA. ·J Clin Oncol · Pubmed #25987699.

ABSTRACT: -- No abstract --

277 Editorial Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. 2015

Carnevale, Julia / Ashworth, Alan. ·University of California, San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA. · University of California, San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA Alan.Ashworth@ucsf.edu. ·J Clin Oncol · Pubmed #25987697.

ABSTRACT: -- No abstract --

278 Editorial Pancreatic cancer: gradual rise, increasing relevance. 2015

Sitas, Freddy / Neale, Rachel E / Weber, Marianne F / Luo, Qingwei. ·Cancer Council NSW, Sydney, NSW, Australia. freddy.sitas@gmail.com. · QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. · Cancer Council NSW, Sydney, NSW, Australia. ·Med J Aust · Pubmed #25929490.

ABSTRACT: -- No abstract --

279 Editorial Pancreatic oncogenic signaling cascades converge at Protein Kinase D1. 2015

Liou, Geou-Yarh / Leitges, Michael / Storz, Peter. ·a Department of Cancer Biology ; Mayo Clinic Comprehensive Cancer Center; Mayo Clinic ; Jacksonville , FL USA. ·Cell Cycle · Pubmed #25928263.

ABSTRACT: -- No abstract --

280 Editorial Somatostatin receptor subtype 2 as pancreatic tumorigenesis suppressor: identification of a new targetable signaling node. 2015

Crawford, Howard C. ·Departments of Molecular & Integrative Physiology and Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: howcraw@umich.edu. ·Gastroenterology · Pubmed #25921374.

ABSTRACT: -- No abstract --

281 Editorial Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. 2015

Hoffman, Robert M / Bouvet, Michael. ·AntiCancer, Inc. , 7917 Ostrow Street, San Diego, 92111 CA , USA +1 858 654 2555 ; +1 858 268 4175 ; all@anticancer.com. ·Expert Opin Pharmacother · Pubmed #25887245.

ABSTRACT: Nanoparticle albumin-bound (nab)-paclitaxel is paclitaxel linked to albumin nanoparticles, which makes it soluble and is an example of an application of nanotechnology for cancer treatment. The development of nanotechnology as a delivery system for nab-paclitaxel has improved the pharmacokinetics and pharmacodynamics of paclitaxel, in part by decreasing its hydrophobicity. Nab-paclitaxel in combination with gemcitabine has slightly improved survival in pancreatic cancer, compared to gemcitabine alone, as demonstrated in Phase III clinical trials. Cell cycle phase-specific drugs, such as nab-paclitaxel, which target cells in the G2/M phase of the cell cycle, can only have limited efficacy since the vast majority of cells in a tumor are quiescent in G0/G1 phase. Recent advances in our laboratory on how to decoy cancer cells to cycle and then trap them in a sensitive phase of the cell cycle, can, in the hopefully near future, allow drugs such as nab-paclitaxel to have high efficacy, even in a treatment-resistant tumor such as pancreatic cancer.

282 Editorial Management of pancreatic mucinous cystic neoplasms: surgery or surveillance? 2015

Hart, Phil A / Chari, Suresh T. ·Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, MN, USA; Division of Gastroenterology, Hepatology, & Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, MN, USA. Electronic address: chari.suresh@mayo.edu. ·Pancreatology · Pubmed #25841313.

ABSTRACT: -- No abstract --

283 Editorial Is there a role for endoscopic ultrasound-guided fine-needle biopsy in pancreatic cancer? 2015

Hébert-Magee, Shantel. ·Center for Interventional Endoscopy, Florida Hospital, Orlando, Florida, United States. ·Endoscopy · Pubmed #25826166.

ABSTRACT: -- No abstract --

284 Editorial Update on the management of pancreatic cancer: surgery is not enough. 2015

Ansari, Daniel / Gustafsson, Adam / Andersson, Roland. ·Daniel Ansari, Adam Gustafsson, Roland Andersson, Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, SE-221 85 Lund, Sweden. ·World J Gastroenterol · Pubmed #25805920.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) represents the fourth cause of death in cancer and has a 5-year survival of < 5%. Only about 15% of the patients present with a resectable PDAC with potential to undergo "curative" surgery. After surgery, local and systemic recurrence, is though very common. The median survival of resected patients with adjuvant chemotherapy after surgery is only 20-23 mo. This underscores the significant need to improve PDAC management strategies. Increased survival rate is dependent on new breakthroughs in our understanding of not at least tumor biology. The aim of this review is to update and comment on recent knowledge concerning PDAC biology and new diagnostics and treatment modalities. One fundamental approach to improve survival rates is by earlier and improved diagnosis of the disease. In recent years, novel blood-based biomarkers have emerged based on genetic, epigenetic and protein changes in PDAC with very promising results. For biomarkers to enter clinical practice they need to have been developed using adequate control groups and provide high sensitivity and specificity and by this identify patients at risk already in a pre-symptomatic stage. Another way to improve outcomes, is by employing neoadjuvant treatments thereby increasing the number of resectable cases. Novel systemic treatment regimes like FOLFIRINOX and nab-paclitaxel have demonstrated improvements in prolonging survival in advanced cases, but long-term survival is still scarce. The future improved understanding of PDAC biology will inevitably render new treatment options directed against both the cancer cells and the surrounding microenvironment.

285 Editorial Mesopancreas: A boundless structure, namely the rationale for dissection of the paraaortic area in pancreaticoduodenectomy for pancreatic head carcinoma. 2015

Peparini, Nadia. ·Nadia Peparini, Azienda Sanitaria Locale Roma H- Distretto 3, 00043 Ciampino (Rome), Italy. ·World J Gastroenterol · Pubmed #25780282.

ABSTRACT: This review highlights the rationale for dissection of the 16a2 and 16b1 paraaortic area during pancreaticoduodenectomy (PD) for carcinoma of the head of the pancreas. Recent advances in surgical anatomy of the mesopancreas indicate that the retropancreatic area is not a single entity with well defined boundaries but an anatomical site of embryological fusion of peritoneal layers, and that continuity exists between the neuro lymphovascular adipose tissues of the retropancreatic and paraaortic areas. Recent advances in surgical pathology and oncology indicate that, in pancreatic head carcinoma, the mesopancreatic resection margin is the primary site for R1 resection, and that epithelial-mesenchymal transition-related processes involved in tumor progression may impact on the prevalence of R1 resection or local recurrence rates after R0 surgery. These concepts imply that mesopancreas resection during PD for pancreatic head carcinoma should be extended to the paraaortic area in order to maximize retropancreatic clearance and minimize the likelihood of an R1 resection or the persistence of residual tumor cells after R0 resection. In PD for pancreatic head carcinoma, the rationale for dissection of the paraaortic area is to control the spread of the tumor cells along the mesopancreatic resection margin, rather than to control or stage the nodal spread. Although mesopancreatic resection cannot be considered "complete" or "en bloc", it should be "extended as far as possible" or be "maximal", including dissection of 16a2 and 16b1 paraaortic areas.

286 Editorial Should sphincterotomy be performed before placement of metal stents for biliary obstruction in patients with unresectable pancreatic cancer? 2015

Yang, Dennis / Draganov, Peter V. ·Division of Gastroenterology, Mount Sinai Hospital, New York, New York. · Division of Gastroenterology and Hepatology, University of Florida, Gainesville, Florida. ·Clin Gastroenterol Hepatol · Pubmed #25737439.

ABSTRACT: -- No abstract --

287 Editorial Management of pancreatic cysts: the evidence is not here yet. 2015

Fernández-Del Castillo, Carlos / Tanaka, Masao. ·Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts. · Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan. ·Gastroenterology · Pubmed #25724457.

ABSTRACT: -- No abstract --

288 Editorial Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? 2015

Bergsland, Emily K. ·University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA emilyb@medicine.ucsf.edu. ·J Clin Oncol · Pubmed #25646187.

ABSTRACT: -- No abstract --

289 Editorial Therapeutic advances in pancreatic cancer: miles to go before we sleep. 2015

Bekaii-Saab, Tanios / Goldberg, Richard. ·Ohio State University Comprehensive Cancer Center, Columbus, OH (TBS, RG). Tanios.Saab@osumc.edu. · Ohio State University Comprehensive Cancer Center, Columbus, OH (TBS, RG). ·J Natl Cancer Inst · Pubmed #25638250.

ABSTRACT: -- No abstract --

290 Editorial Is plastic stenting for pancreatic cancer still relevant or obsolete in 2015? 2015

Wang, Andrew Y. ·Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA. ·Gastrointest Endosc · Pubmed #25616754.

ABSTRACT: -- No abstract --

291 Editorial Identifying molecular targets to improve immune function in alcoholic hepatitis. 2015

Bataller, Ramon / Mandrekar, Pranoti. ·Division of Gastroenterology and Hepatology, Departments of Medicine and Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: bataller@med.unc.edu. · Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. ·Gastroenterology · Pubmed #25613314.

ABSTRACT: -- No abstract --

292 Editorial The changing liver transplant waitlist: an emerging liver purgatory? 2015

Asrani, Sumeet K / O'Leary, Jacqueline G. ·Baylor University Medical Center, Dallas, Texas. · Baylor University Medical Center, Dallas, Texas. Electronic address: Jacquelo@BaylorHealth.edu. ·Gastroenterology · Pubmed #25613312.

ABSTRACT: -- No abstract --

293 Editorial Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. 2015

Humphris, Jeremy / Chang, David K / Biankin, Andrew V. ·The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia. · Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia; Faculty of Medicine, St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; Department of Surgery, Bankstown Hospital, Bankstown, Sydney, New South Wales, Australia; Faculty of Medicine, South Western Sydney Clinical School, University of New South Wales, Liverpool, Australia. · Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia; Faculty of Medicine, St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; Department of Surgery, Bankstown Hospital, Bankstown, Sydney, New South Wales, Australia; Faculty of Medicine, South Western Sydney Clinical School, University of New South Wales, Liverpool, Australia. Electronic address: Andrew.Biankin@glasgow.ac.uk. ·Gastroenterology · Pubmed #25613311.

ABSTRACT: -- No abstract --

294 Editorial Precision immunology: the promise of immunotherapy for the treatment of cancer. 2015

Kaufman, Howard L. ·Rutgers Cancer Institute of New Jersey, New Brunswick, NJ howard.kaufman@rutgers.edu. ·J Clin Oncol · Pubmed #25605852.

ABSTRACT: -- No abstract --

295 Editorial Neoadjuvant therapy for localized pancreatic cancer: support is growing? 2015

Evans, Douglas B / Ritch, Paul S / Erickson, Beth A. ·From the Pancreatic Cancer Program, Departments of Surgery, Medicine, and Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI. ·Ann Surg · Pubmed #25599323.

ABSTRACT: -- No abstract --

296 Editorial p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway? 2015

Azmi, Asfar S / Mohammad, Ramzi M. ·Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 732, Detroit, MI 48201, USA. ·Future Med Chem · Pubmed #25582328.

ABSTRACT: -- No abstract --

297 Editorial Additional support for neoadjuvant therapy in the management of pancreatic cancer. 2015

Christians, Kathleen K / Evans, Douglas B. ·Pancreatic Cancer Program and the Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA, kchristi@mcw.edu. ·Ann Surg Oncol · Pubmed #25519932.

ABSTRACT: -- No abstract --

298 Editorial FOLFIRINOX: desert, oasis, or mirage? 2015

Ferrone, Cristina R. ·Massachusetts General Hospital, Surgery, Boston, MA, USA, cFERRONE@mgh.harvard.edu. ·Ann Surg Oncol · Pubmed #25490873.

ABSTRACT: -- No abstract --

299 Editorial Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact. 2015

Roesli, Christoph. ·Junior Research Group Biomarker Discovery, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. ·Expert Rev Proteomics · Pubmed #25407217.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a median overall survival of 6 months. Late diagnosis due to the absence of specific symptoms during disease development, in addition to extensive metastatic potential and resistance to chemotherapy and radiotherapy, are the most important reasons for short survival. Research efforts have therefore been focused on the development of early disease detection. However, the only US FDA-approved clinical biomarker, CA19-9, is considered inapplicable for screening and/or early detection of PDAC. The following editorial provides the reader with a short introduction to the topic of PDAC and gives focus to the current state of proteomic research in the field of PDAC biomarker discovery. This editorial also highlights the efforts made to subdivide this tumor entity and the potential clinical impact of patient stratification. Finally, the author provides opinions on the impact of proteomics to PDAC subtype stratification over the next 5 years.

300 Editorial [Chemo-sensitivity study in pancreatic cancer]. 2014

Lee, Kwang Hyuck. · ·Korean J Gastroenterol · Pubmed #25675541.

ABSTRACT: -- No abstract --

Back · Next